

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Vitamin D3 in ICU COVID-19 patients, cognitive deficits in long COVID, knowledge mobilisation, Evusheld for immunocompromised patients

Peer reviewed journals featured:

- Randomised controlled trials of:
 - Vitamin D3 supplementation for COVID-19 patients admitted to the ICU [here](#)
 - High-dose coenzyme Q10 therapy in patients with post COVID-19 condition [here](#)
- Narrative reviews on:
 - Challenges and opportunities for educating health professionals after COVID-19 [here](#)
 - A multinational Delphi consensus on how to end the COVID-19 public health threat [here](#)
 - Pragmatic and open science-based reporting of living systematic reviews [here](#)
- Observational studies on:
 - Cognitive deficits in long COVID-19 [here](#)
 - The complexity and challenges of diagnosing and managing long COVID [here](#)
 - Immunosuppression and immunotherapy in patients with cancer and COVID-19 [here](#)
 - Bivalent COVID-19 mRNA vaccine booster doses in persons aged 12+ years [here](#)
 - Viral load dynamics of Delta and Omicron after vaccine doses and infection [here](#)
 - Omicron protection from vaccination and previous infection in a California prison [here](#)
 - Long-lasting symptoms after COVID-19 and factors associated with resolution [here](#)
 - Severe neurologic involvement in US paediatric inpatients with COVID-19 [here](#)
 - Kidney function and mortality after COVID-19-associated acute kidney injury [here](#)
 - Neuro-COVID, peripheral immune signatures, autoimmunity, & neurodegeneration [here](#)
 - The effect of inequitable global COVID-19 vaccine coverage [here](#)
 - Lifting universal masking in schools in the US [here](#)
- An editorial on face coverings for young school-aged children [here](#)
- Commentary on:
 - Vaccination and protective immunity to Omicron in people with immunodeficiencies [here](#)
 - The impact of COVID-19 on diabetes services [here](#)
 - Effective knowledge mobilisation in response to COVID-19 [here](#)

Letters and correspondence discussed:

- Six-month follow-up after a fourth Comirnaty (Pfizer) vaccine dose [here](#)
- Myocarditis after Comirnaty (Pfizer) vaccination in Israeli adolescents [here](#)
- Rate of recurrence after discontinuing anticoagulation therapy in patients with COVID-19–associated venous thromboembolism [here](#)

Pre-peer review articles featured:

- Rehabilitation in survivors of COVID-19 (RE2SCUE) [here](#)
- Prevalence of long COVID [here](#)
- Tixagevimab/cilgavimab (Evusheld) for COVID-19 prophylaxis in immunocompromised patients [here](#)
- Prior infections and effectiveness of COVID-19 vaccine in test-negative study [here](#)
- COVID-19 related changes in eating disorder pathology, emotional and binge eating [here](#)
- Bivalent Comirnaty (Pfizer) original/Omicron BA.4-5 booster vaccination [here](#)
- COVID-19 (Omicron strain) hospital admissions from a virtual ward [here](#)
- Real-world effectiveness of nirmatrelvir/ritonavir (Paxlovid) for COVID-19 in Ontario [here](#)
- Nirmatrelvir and the risk of long COVID [here](#)
- Three-month antibody persistence of a bivalent Omicron-containing booster COVID-19 vaccine [here](#)

Guidance and reports

- The World Health Organization published its weekly COVID-19 epidemiological report [here](#)
- The European Centre for Disease Prevention and Control (ECDC) published a report on prevalence of post COVID-19 condition symptoms [here](#)

News and blogs

- England's health declined in 2020, but not across all areas [here](#)
- Evusheld protects the most vulnerable patients [here](#)
- Charging French former health minister with endangering lives was “very unjust,” [here](#)
- The US faces triple epidemic of flu, RSV, and COVID-19 [here](#)
- Pandemic disruption linked to 30 000 excess heart disease deaths in England [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).

